AbbVie's hepatitis C regimen wins breakthrough designation from FDA

05/7/2013 | Chicago Tribune (tiered subscription model) · RTT News

The FDA granted breakthrough therapy status to AbbVie's experimental direct-acting antiviral regimen, with and without ribavirin, as a therapy for genotype 1 hepatitis C virus. The combo is in late-stage trials in 29 nations.

View Full Article in:

Chicago Tribune (tiered subscription model) · RTT News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Pompano Beach, FL